Mara Fornaro,John Xu,Yuan Gao,Rainer Hillenbrand,Francois Legay,Daniela Stoellner
申请号：
US13128335
公开号：
US08753632B2
申请日:
2009.11.10
申请国别(地区):
US
年份:
2014
代理人:
摘要：
High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.
